Michael Castagna, an insider at MannKind Corp (MNKD), sold 2,504,792 shares of the company's stock on December 15, 2025, at a price of $6.00 per share, resulting in a total transaction value of $15.03 million. Following this sale, Castagna retains an equal number of shares in the company.
MannKind, headquartered in Danbury, Connecticut, is a biopharmaceutical firm focused on developing innovative therapeutic products for serious unmet medical needs, particularly in the areas of cardiometabolic and orphan lung diseases. The company's commercial offerings include Afrezza, an ultra-rapid-acting inhaled insulin, and the V-Go wearable insulin delivery device. MannKind also markets Tyvaso DPI, used for treating pulmonary arterial hypertension.
As of November 25, 2025, MannKind boasts a market capitalization of $1.6 billion, with a price-to-earnings ratio of 54.78 and earnings per share of 0.09. The company is scheduled to report its earnings on May 6, 2026, with an estimated EPS of $0.01 and revenue of $101.5 million.
Insider transactions such as this one must be reported to the SEC, providing transparency into the actions of company executives. While such sales can occur for various reasons, including personal financial needs, they should be viewed in the context of broader insider activity rather than as isolated events. Investors are encouraged to consider patterns across multiple insiders and time frames when assessing insider trading signals.